Infectious Disease Programs News

This is selected news for Infectious Disease Programs, which is filed under Healthcare Topics. There are 146 news items for this page. A press release filter page is also available for Infectious Disease Programs.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/18/2022 Within A Month After Pulling Plug On COVID-19 Booster Study, Inovio Shelves Two More Infectious Disease Programs - Inovio Pharmaceuticals (NASDAQ:INO) - Benzinga
Inovio Pharmaceuticals Inc INO has agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations ( CEPI ), to discontinue the development of product candidates targeting Lassa Fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700). Recently, Inovio discontinued its internally funded efforts to develop INO-4800 as a COVID ...
Benzinga
11/2/2022 SystemOne Launches Multi-Instrument Medical Diagnostic Network in Tanzania | Business Wire
... sustainability and security. ‚AuThe health authorities at the National Tuberculosis and Leprosy Program (NTLP) in Tanzania understand how information is critical to assess and manage infectious disease programs,‚Au said Chris Macek, CEO, SystemOne. ‚AuInformation is at the heart of the diagnostic network, and transmitting information rapidly and purposefully helps ...
Business Wire
11/2/2022 SystemOne Launches Multi-Instrument Medical Diagnostic Network in Tanzania - Africa Briefing
... sustainability and security. ‚AuThe health authorities at the National Tuberculosis and Leprosy Program (NTLP) in Tanzania understand how information is critical to assess and manage infectious disease programs,‚Au said Chris Macek, CEO, SystemOne. ‚AuInformation is at the heart of the diagnostic network, and transmitting information rapidly and purposefully helps ...
africabriefing.com
10/29/2022 Director of Chemmistry
... medicinal chemistry strategies, lead, motivate and mentor a team of skilled PhD/MS/BS chemists, and participate in cross functional project teams to advance Microbiotix infectious disease programs. Qualifications: A Ph.D. in organic or medicinal chemistry is required. 15+ years‚Ao industrial experience and 7+ years managing a discovery medicinal ...
monster.com
10/25/2022 Gritstone bio Announces Private Placement of $45.0 Million
... subject to customary closing conditions. Gritstone intends to use the net proceeds from the PIPE financing to fund the ongoing clinical development of oncology and infectious disease programs and for general corporate purposes. The financing is being led by Redmile Group, with participation from new and existing investors, including Gilead ...
Globe Newswire
10/25/2022 Gritstone bio Announces Private Placement of $45.0 Million
... subject to customary closing conditions. Gritstone intends to use the net proceeds from the PIPE financing to fund the ongoing clinical development of oncology and infectious disease programs and for general corporate purposes. The financing is being led by Redmile Group, with participation from new and existing investors, including Gilead ...
Yahoo News
10/25/2022 2022-10-25 | NYSE:HTGC | Press Release | Hercules Capital Inc.
... subject to customary closing conditions. Gritstone intends to use the net proceeds from the PIPE financing to fund the ongoing clinical development of oncology and infectious disease programs and for general corporate purposes. The financing is being led by Redmile Group, with participation from new and existing investors, including Gilead ...
stockhouse.com
10/25/2022 Gritstone bio to sell 6.6M shares for gross proceeds of ~$45M
... to close on Oct. 27. - Net proceeds from the private placement are intended to be used to fund the ongoing clinical development of oncology and infectious disease programs and for general corporate purposes. - GRTS shares were trading +6.19% pre-market. - Source: Press Release ...
Seeking Alpha
10/15/2022 Health care prepares for third winter surge
... COVID-19 cases will rise as the weather changes. ‚AuWe‚Aore certainly prepared for this winter,‚Ao‚Ao said Emily Shears, who heads UPMC's infectious disease programs in its northern hospital systems, including UPMC Horizon's campuses in Farrell and Greenville, and UPMC Jameson in New Castle. Healthcare providers ...
sharonherald.com
10/3/2022 Recce Pharmaceuticals Announces Expansion and Acceleration
... made in the last 12 months continues to strengthen and build out the Company's anti-infective platform, paving the way to new and considerable infectious disease programs across a range of unmet medical needs,‚Au said James Graham, Chief Executive Officer of Recce Pharmaceuticals. ‚AuWith good safety and encouraging ...
Globe Newswire
9/28/2022 ADRA Yemen - MONITORING, EVALUATION, LEARNING DIRECTOR- Yemen Mission Round MOMENTUM APS
... years working on monitoring, evaluation, research, and learning in the field of public health, HIV/AIDS, maternal and child health, family planning, and/or other infectious disease programs, as well as knowledge of monitoring of results-based financing programs preferably with USAID funded projects - Minimum of 5 years of experience ...
reliefweb.int
9/7/2022 Recce Pharmaceuticals Appoints Alistair McKeough to its
... appointments are effective as of Sept. 1, 2022. ‚AuStrengthening the board's corporate governance has been an area of key focus as the Company's infectious disease programs move ahead and become institutionally relevant, locally and overseas,‚Au said John Prendergast, Ph.D., Charmain of Recce Pharmaceuticals. ‚AuThe board and I ...
Globe Newswire
9/7/2022 Recce Pharmaceuticals (RCE) Recce Pharmaceuticals Appoints Alistair McKeough to its Board of Directors
... appointments are effective as of Sept. 1, 2022. ‚AuStrengthening the board's corporate governance has been an area of key focus as the Company's infectious disease programs move ahead and become institutionally relevant, locally and overseas,‚Au said John Prendergast, Ph.D., Charmain of Recce Pharmaceuticals. ‚AuThe board and I ...
researchpool.com
9/7/2022 Recce Pharmaceuticals Appoints Alistair McKeough to its Board of Directors
... appointments are effective as of Sept. 1, 2022. ‚AuStrengthening the board's corporate governance has been an area of key focus as the Company's infectious disease programs move ahead and become institutionally relevant, locally and overseas,‚Au said John Prendergast, Ph.D., Charmain of Recce Pharmaceuticals. ‚AuThe board and I ...
biotechwinners.com
8/25/2022 2022-08-24 | NDAQ:HRZN | Press Release | Horizon Technology Finance Corporation
... life science companies,” said Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. ‚AuWe anticipate a number of important milestones across our oncology and infectious disease programs. This transaction immediately strengthens our balance sheet and provides the financial resources necessary to advance the company’s clinical pipeline. We ...
stockhouse.com
8/25/2022 Horizon Technology Finance Provides $35MM Term Loan to PDS Biotechnology
... supporting innovative life science companies,‚Au Frank Bedu-Addo, CEO of PDS Biotech, said. ‚AuWe anticipate a number of important milestones across our oncology and infectious disease programs. This transaction immediately strengthens our balance sheet and provides the financial resources necessary to advance the company's clinical pipeline. We look ...
abfjournal.com
8/25/2022 PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance
... life science companies,‚Au said Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. ‚AuWe anticipate a number of important milestones across our oncology and infectious disease programs. This transaction immediately strengthens our balance sheet and provides the financial resources necessary to advance the company's clinical pipeline. We look ...
pharmaceuticaldaily.com
8/25/2022 PDS Biotech completes $35mn financing agreement led by Horizon Technology Finance - Recipes and Stuff
... specialty finance company that has an extensive history of supporting innovative life science companies. ‚AuWe anticipate a number of important milestones across our oncology and infectious disease programs. This transaction immediately strengthens our balance sheet and provides the financial resources necessary to advance the company's clinical pipeline. We look ...
recipes-stuff.com
8/24/2022 PDS Biotech Completes $35 Million Financing Agreement Led
... life science companies,‚Au said Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. ‚AuWe anticipate a number of important milestones across our oncology and infectious disease programs. This transaction immediately strengthens our balance sheet and provides the financial resources necessary to advance the company's clinical pipeline. We look ...
Globe Newswire
8/24/2022 PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance
... life science companies,‚Au said Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. ‚AuWe anticipate a number of important milestones across our oncology and infectious disease programs. This transaction immediately strengthens our balance sheet and provides the financial resources necessary to advance the company's clinical pipeline. We look ...
Yahoo News
8/24/2022 Navajo Nation awaits the first shipment of monkeypox vaccine
... determined to be at high risk for monkeypox infection. ‚AuThey are recommended for people who have been exposed,‚Au said Dr. Laura Hammitt, director of infectious disease programs at Johns Hopkins University's Center for American Indian Health. She noted the CDC recommends the vaccine be administered to people identified as ...
azcentral.com
8/16/2022 Merck Makes Another Big R&D Investment with $3.5B Orna Deal | BioSpace
... collaboration streak, Merck is pouring a potential $3.5 billion into a partnership with circular RNA company Orna Therapeutics to develop and commercialize multiple oncology and infectious disease programs. Under the terms of the deal, Orna will receive $150 million by the third quarter of this year. The biotech, which launched ...
BioSpace
8/11/2022 Why Inovio Pharmaceuticals Is Gaining Today
... closest program to commercialization is its coronavirus vaccine, which is in phase 3 trials, though it also has a few other early and mid-stage infectious disease programs in the works, like its Middle East Respiratory Syndrome (MERS) vaccine in phase 2 trials. Inovio's net loss of $108.5 million in ...
newsbreak.com
8/10/2022 Inovio Pharmaceuticals, Inc. (INO) CEO Jacqueline Shea on Q2 2022 Results - Earnings Call Transcript
... across our IO portfolio as well as our HPV-related portfolio. And then on the intradermal or ID side, which we've been using across our infectious disease programs, we have our new 3PSP device which is a handheld device as well as our historical CELLECTRA device, which has mainly been ...
Seeking Alpha
8/10/2022 Inovio Pharmaceuticals (INO) Q2 2022 Earnings Call Transcript | Nasdaq
... across our IO portfolio as well as our HPV-related portfolio. And then on the intradermal or ID side, which we've been using across our infectious disease programs, we have our new 3PSP device which is a handheld device as well as our historical CELLECTRA device, which has mainly been ...
Nasdaq